Literature DB >> 21274673

Clinical and prognostic value of the presence of irregular giant nuclear cells in pT1 ovarian clear cell carcinoma.

Naoki Matsumoto1, Takashi Umezawa, Toru Sasaki, Kuninobu Nakajima, Yukiko Kanetsuna, Hiroshi Sasaki.   

Abstract

In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7-124 and adjusted hazard ratio = 25, 95% confidence interval =  2.9-768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%, P = 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.

Entities:  

Mesh:

Year:  2011        PMID: 21274673     DOI: 10.1007/s12253-010-9356-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  25 in total

1.  Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5.

Authors:  M A Bookman; B E Greer; R F Ozols
Journal:  Int J Gynecol Cancer       Date:  2003 Nov-Dec       Impact factor: 3.437

2.  Prognostic ability of simplified nuclear grading of renal cell carcinoma.

Authors:  Nathalie Rioux-Leclercq; Pierre I Karakiewicz; Quoc-Dien Trinh; Vincenzo Ficarra; Luca Cindolo; Alexandre de la Taille; Jacques Tostain; Richard Zigeuner; Arnaud Mejean; Jean-Jacques Patard
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

3.  Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).

Authors:  N Sakuragi; H Yamada; M Oikawa; K Okuyama; T Fujino; T Sagawa; S Fujimoto
Journal:  Gynecol Oncol       Date:  2000-11       Impact factor: 5.482

4.  Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial.

Authors:  H Utsunomiya; J Akahira; S Tanno; T Moriya; M Toyoshima; H Niikura; K Ito; Y Morimura; Y Watanabe; N Yaegashi
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

5.  Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma.

Authors:  Vincenzo Ficarra; Guido Martignoni; Nicola Maffei; Matteo Brunelli; Giacomo Novara; Luisa Zanolla; Maurizio Pea; Walter Artibani
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

6.  Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?

Authors:  S Suzuki; H Kajiyama; K Shibata; K Ino; A Nawa; K Sakakibara; K Matsuzawa; A Takeda; Y Kinoshita; M Kawai; T Nagasaka; F Kikkawa
Journal:  Ann Oncol       Date:  2008-03-19       Impact factor: 32.976

7.  Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

Authors:  John K Chan; Deanna Teoh; Jessica M Hu; Jacob Y Shin; Kathryn Osann; Daniel S Kapp
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482

8.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

9.  Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma.

Authors:  C Q Liu; H Sasaki; M T Fahey; A Sakamoto; S Sato; T Tanaka
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

10.  Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

Authors:  M Takano; Y Kikuchi; N Yaegashi; K Kuzuya; M Ueki; H Tsuda; M Suzuki; J Kigawa; S Takeuchi; H Tsuda; T Moriya; T Sugiyama
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.